Hyperfine, Inc. (Nasdaq: HYPR), a pioneering health technology company known for its AI-powered portable MRI brain imaging system, the Swoop® system, has announced further global expansion with new distribution agreements in Turkey, Israel, and Saudi Arabia. These agreements are part of Hyperfine’s strategy to expand the reach of its Swoop® system into regions with large populations, limited access to MRI, and significant healthcare challenges. The new partnerships aim to address the unmet need for accessible brain imaging in these countries.
“We have reached significant milestones throughout 2024, positioning us for growth in international markets in 2025,” said David Castiglioni, Chief Commercial Officer at Hyperfine. “Our new distribution partners enhance our global network, allowing us to bring portable MR brain imaging to regions that would benefit greatly from this technology. The demand from international clinicians and healthcare facilities highlights the growing interest in the potential of portable MRI to bridge critical healthcare gaps.”
These new agreements build on Hyperfine’s previous distribution deals in 2024, which target markets across thirteen European countries, as well as India, Malaysia, and Indonesia. The company has already secured CE approval in Europe for its latest ninth-generation AI-powered software, further strengthening its expansion efforts. This extensive distribution network positions Hyperfine for robust growth in the years to come.
The distribution agreements in Turkey, Israel, and Saudi Arabia ensure efficient market entry and provide strong local support for the Swoop® system’s adoption. These regions, with a combined population of over 100 million, face challenges in providing timely neurological care, particularly in remote or emergency settings without access to traditional MRI equipment. The Swoop® system’s portability and affordability eliminate barriers posed by conventional MRI, enabling clinicians to deliver high-quality brain imaging directly at the point of care.
“We believe the Swoop® system can play a vital role in advancing global neurological care,” Castiglioni added. “With lower penetration of traditional MRI in these markets, a portable and affordable brain imaging solution like the Swoop® system is invaluable for addressing the unmet healthcare needs in these regions.”
The Swoop® Portable MR Imaging® system is FDA-cleared for brain imaging of patients of all ages. This ultra-low-field MRI device is portable and designed to produce brain images in settings where full diagnostic exams are not feasible. The system is also CE-certified in Europe and holds UKCA certification for the United Kingdom. It is currently available in select international markets.
Hyperfine, Inc. is committed to revolutionizing patient care by providing accessible, clinically relevant diagnostic imaging through its innovative technologies.
